Benzinga | Jan 26, 2021 09:35AM EST

Aegis Capital Maintains Buy on Kindred Biosciences, Raises Price Target to $16

Aegis Capital analyst Nathan Weinstein maintains Kindred Biosciences (NASDAQ:KIN) with a Buy and raises the price target from $14 to $16.